Vysali Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 5.43 Cr
- Company Age 45 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 30.26 Cr
- Satisfied Charges ₹ 19.46 Cr
- Revenue Growth -38.63%
- Profit Growth 25.91%
- Ebitda 10.32%
- Net Worth -8.98%
- Total Assets -3.13%
About Vysali Pharmaceuticals
Company Details
-
Location
Ernakulam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24231KL1979PLC003112
-
Company No.
003112
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
29 Oct 1979
-
Date of AGM
26 Nov 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Vysali Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alathur Krishnan
|
Managing Director | 29-Oct-1979 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Savithri Krishnan
|
Whole-Time Director | 29-Oct-1979 | Current |
|
Valath Sheelavelappan
|
Additional Director | 27-Sep-2019 | Current |
Financial Performance of Vysali Pharmaceuticals.
Vysali Pharmaceuticals Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 38.63% decrease. The company also saw a substantial improvement in profitability, with a 25.91% increase in profit. The company's net worth dipped by a decrease of 8.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vysali Pharmaceuticals?
In 2021, Vysali Pharmaceuticals had a promoter holding of 10.54% and a public holding of 89.45%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹30.26 Cr
₹19.46 Cr
Charges Breakdown by Lending Institutions
- Kerala State Industrial Development Corpn Ltd : 11.17 Cr
- Kerala State Industrial Development Corporation Limited : 11.17 Cr
- Kerala State Industrial Development Corportion Limited : 4.00 Cr
- Others : 3.00 Cr
- The Kerala State Industrial Development Corp. Ltd : 0.50 Cr
- Others : 0.42 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Sep 2019 | Others | ₹3.00 Cr | Open |
| 25 Oct 2007 | Kerala State Industrial Development Corporation Limited | ₹5.59 Cr | Open |
| 24 Oct 2007 | Kerala State Industrial Development Corporation Limited | ₹5.59 Cr | Open |
| 14 Jun 2007 | Kerala State Industrial Development Corpn Ltd | ₹5.59 Cr | Open |
| 13 Jun 2007 | Kerala State Industrial Development Corpn Ltd | ₹5.59 Cr | Open |
How Many Employees Work at Vysali Pharmaceuticals?
Vysali Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vysali Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vysali Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
